Research archive · Melanocortin peptide
PT-141 is a brain-acting peptide studied for sexual desire — here is what the research actually shows.
A plain-English archive of the published studies on the melanocortin peptide: how it works, what the trials measured, and the honest caveats — sources ruled beneath each entry.
The short version
PT-141 is a lab-made peptide (a short chain of amino acids, the building blocks of proteins). Its drug name is bremelanotide. It is unusual because it works in the brain, not in the blood vessels — it switches on receptors called melanocortin receptors that sit in the part of the brain that controls sexual desire [1]. That makes it different from the well-known erection pills, which work by opening up blood flow.
Where does the evidence stand? In the United States, PT-141 is an approved prescription medicine for one specific group: premenopausal women diagnosed with low sexual desire that causes them distress (a condition doctors call HSDD) [3][7]. Two large trials backed that approval [3]. In men, PT-141 was tested in earlier studies for erection problems and produced real effects [1][8], but it was never approved for men — so any use in men is off-label and still investigational. This site explains all of it in plain words. The benefits people talk about, the side effects, and the cautions are on PT-141 effects.
What is PT-141
PT-141 is a synthetic copy, with small tweaks, of a natural body signal called alpha-MSH (alpha-melanocyte-stimulating hormone — a messenger your body already makes) [1]. Chemists built it as a ring-shaped peptide of seven amino acids (a cyclic heptapeptide), which makes it more stable than a plain straight chain [7]. Its formal drug name is bremelanotide, and its research-chemical name is PT-141. They are the same molecule [7].
The key idea is where it acts. PT-141 turns on melanocortin receptors — chiefly one called MC4R (melanocortin 4 receptor) — that are concentrated in the hypothalamus, a control hub deep in the brain [1][13]. By doing that, it appears to nudge the brain circuits and dopamine signaling tied to wanting and arousal [1][5]. It does not act on the plumbing of the penis the way an erection pill does, and it does not raise testosterone [1]. That single fact — it works through the brain — is the thread that runs through the whole archive.
What the studies have demonstrated
Across rat and monkey studies, giving PT-141 produced erections and lit up neurons in the hypothalamus (measured by a marker called c-Fos that flags recently active brain cells), and in men with erectile dysfunction it produced rapid, dose-dependent erectile activity [1]. That early human signal is what pushed the molecule into clinical development.
The strongest human evidence is in women. Two identical, large Phase 3 trials (called RECONNECT, with 1,267 premenopausal women who had low sexual desire with distress) found that a 1.75 mg injection used as needed improved desire and lowered the distress tied to it, compared with a dummy injection, over 24 weeks [3]. A 52-week follow-up showed the benefit held up with no new safety surprises, though nausea was common [4]. A brain-imaging study in 2022 went further and watched the mechanism directly: switching on MC4R increased desire and changed how the brain processed erotic images [5]. The effects are real and repeatedly measured — and, importantly, the approved use is narrow. The honest caveats live on PT-141 effects.
How it is different from erection pills
The common erection pills are PDE-5 inhibitors. They work at the periphery — relaxing the smooth muscle in blood vessels so more blood can flow into the penis. PT-141 works at the center — in the brain's desire circuitry [1]. One is plumbing; the other is the signal that starts the process.
That difference is why researchers once studied the two together. A small study combined a low dose of PT-141 with a PDE-5 inhibitor in men and reported an enhanced erectile response — the idea being that a central trigger plus peripheral blood flow might add up [10]. It is also why a common online claim is simply wrong: PT-141 is not a PDE-5 inhibitor and does not raise testosterone [1]. See the full mechanism on PT-141 research and the men's-research summary on PT-141 for men.